Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Getting Alzheimer's blood test results sooner makes a real difference. A randomized trial found that early disclosure of plasma biomarker results dramatically boosted physicians' diagnostic confidence and led to earlier treatment — all without increasing patient anxiety or depression. It's a strong case for moving these tests earlier in the clinical workflow.
A first-of-its-kind randomized trial published in JAMA Neurology shows that disclosing Alzheimer's blood biomarker results earlier in the diagnostic process doesn't just confirm what clinicians suspect — it actively changes how they manage patients. The PLASMAR trial enrolled 220 patients being evaluated for cognitive symptoms at a memory clinic in Spain, randomizing them to receive plasma p-tau217 and neurofilament light chain (NfL) results at either 3 or 9 months.
The impact was striking. Early access to results boosted the proportion of patients with very high diagnostic certainty (≥90%) from just 4.6% to 50% at the 3-month mark. Clinicians with earlier results also initiated treatment more often and streamlined care pathways — sending more patients back to primary care and ordering fewer repeat neuropsychological assessments.
Key Takeaways:
Why it matters: These findings shift the conversation around Alzheimer's blood tests from "how accurate are they?" to "do they actually help?" The answer, it turns out, is yes — earlier results mean earlier, more targeted care decisions, less unnecessary specialist follow-up, and no added psychological burden for patients.
